NR1H4 and Insulin resistance: PXR mice exhibit FXR agonist therapeutic trials in humans have reported reduced liver lipid accumulation and increased glucose uptake [reviewed in (110)], reduced HDL cholesterol and increased LDL cholesterol, and improvements in insulin resistance [reviewed in (111)], suggesting that FXR antagonists and/or selective FXR receptor modulators might promote more beneficial effects in some tissues and for specific metabolic endpoints (116).